- Home
- CELC vs IGD Comparison
CELC vs IGD Comparison
Compare CELC & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- IGD
- Stock Information
- Founded
- CELC 2011
- IGD N/A
- Country
- CELC United States
- IGD United States
- Employees
- CELC N/A
- IGD N/A
- Industry
- CELC Medical Specialities
- IGD Trusts Except Educational Religious and Charitable
- Sector
- CELC Health Care
- IGD Finance
- Exchange
- CELC Nasdaq
- IGD Nasdaq
- Market Cap
- CELC 440.0M
- IGD 456.6M
- IPO Year
- CELC 2017
- IGD N/A
- Fundamental
- Price
- CELC $13.77
- IGD $5.79
- Analyst Decision
- CELC Strong Buy
- IGD
- Analyst Count
- CELC 6
- IGD 0
- Target Price
- CELC $30.67
- IGD N/A
- AVG Volume (30 Days)
- CELC 245.9K
- IGD 215.3K
- Earning Date
- CELC 08-13-2025
- IGD 01-01-0001
- Dividend Yield
- CELC N/A
- IGD 9.15%
- EPS Growth
- CELC N/A
- IGD N/A
- EPS
- CELC N/A
- IGD N/A
- Revenue
- CELC N/A
- IGD N/A
- Revenue This Year
- CELC N/A
- IGD N/A
- Revenue Next Year
- CELC N/A
- IGD N/A
- P/E Ratio
- CELC N/A
- IGD N/A
- Revenue Growth
- CELC N/A
- IGD N/A
- 52 Week Low
- CELC $7.58
- IGD $4.60
- 52 Week High
- CELC $19.77
- IGD $5.26
- Technical
- Relative Strength Index (RSI)
- CELC 59.12
- IGD 51.71
- Support Level
- CELC $13.47
- IGD $5.72
- Resistance Level
- CELC $14.57
- IGD $5.86
- Average True Range (ATR)
- CELC 0.65
- IGD 0.06
- MACD
- CELC -0.04
- IGD -0.01
- Stochastic Oscillator
- CELC 36.65
- IGD 46.43
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About IGD Voya Global Equity Dividend and Premium Opportunity Fund
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.